fda stopping compounded tirzepatide Says Shortage of GLP-1 Is Over Can NPs Prescribe Compounded Tirzepatide
Description
As of April 1, 2026, the FDA issued updated guidance stating that the GLP-1 supply is stabilizing and, with that, prohibiting pharmacies and outsourcing facilities from mass-producing copycat compounded versions of these medications
C., Coxon, A, Mayadas, T
They determine whether GLP-1 therapy is medically appropriate for your specific situation
Opting for compounded semaglutide or tirzepatide, rather than brand-name equivalents, can dramatically reduce the cost of the medication, making it an ideal path for anyone without insurance who wants to utilize these medications
